A cancer patient who lives four hours from the nearest treatment center may qualify for a lifesaving therapy and still never get it, simply because the drive, the lodging, and the paperwork stand in the way.
Quick Take
- Health leaders at the 2026 TIME100 Health Leadership Forum held a panel called “The Access Gap: Expanding Pathways to Life-Saving Care.”
- The discussion focused on cell therapies, treatments that can cure some cancers but are only offered at a small number of specialized centers.
- Faculty physicians from Oregon Health and other institutions joined the panel, moderated by TIME senior health correspondent Alice Park.
- Research shows geography, income, and reimbursement rules all limit who actually receives these treatments once they are approved.
What Happened at the Forum
TIME hosted its 2026 Health Leadership Forum with five expert panels covering different corners of American medicine. One panel, titled “The Access Gap: Expanding Pathways to Life-Saving Care,” brought together faculty physicians who specialize in cell therapies, including doctors from Oregon Health and Science University. The panel’s stated goal was simple: make it easier for patients to actually receive treatments that already exist.
Alice Park moderated the conversation, guiding a discussion built around a hard truth in modern medicine. Scientists have developed remarkable cell therapies capable of curing certain blood cancers. But having a cure on paper means little if patients cannot physically reach the hospitals equipped to deliver it. That gap between invention and delivery formed the spine of the entire panel.
Other sessions that evening tackled related themes, including a panel on the science behind curing cancer, where a speaker stressed that innovation without access “otherwise” fails patients who need it most. The forum’s broader agenda, spanning equitable care, health policy, and mental health for medical workers, showed access wasn’t treated as a side issue but as a central theme running through the night.
Why Cell Therapies Are Hard to Reach
CAR-T therapy, one of the most talked-about cell treatments, is only offered at specialized academic medical centers. Patients often travel hours for evaluation, treatment, and the intensive follow-up monitoring these therapies require. Studies show a drive time of two hours or more cuts the odds of receiving treatment nearly in half compared to patients who live close by. Distance alone can decide who lives cancer-free and who does not.
Money adds another wall. Hospitals treating Medicare patients with CAR-T therapy can lose tens of thousands of dollars per patient because reimbursement rates fall short of actual costs. That financial hit pushes some hospitals to avoid offering the therapy altogether, shrinking the map of available treatment sites even further. Rural and lower-income patients feel this squeeze hardest, since community oncology practices often cannot absorb the loss.
A Pattern Bigger Than One Panel
The forum’s discussion fits a pattern researchers have documented for years. Reviews of cell therapy rollout describe the same obstacles repeating: limited certified centers, complicated manufacturing and monitoring requirements, and reimbursement systems that discourage community hospitals from participating. This isn’t a new complaint invented for a panel discussion. It’s a documented, measurable gap between what science can do and what the health system actually delivers to patients.
Income and geography compound each other in ways that hit specific communities hardest. Research on Medicare patients found that residents of lower-income states had reduced access to CAR-T therapy regardless of medical need. Other studies point to underrepresentation of Black and Hispanic patients in both treatment and clinical trials, adding a layer of disparity on top of the geographic divide.
What Expanding Access Would Actually Require
Closing this gap isn’t just a talking point for a conference stage. It requires real changes: more certified treatment centers outside major cities, reimbursement rates that don’t bankrupt the hospitals willing to offer these therapies, and support systems that help patients cover travel and lodging during weeks of treatment. Health leaders at the forum framed access as “non-negotiable,” a phrase that echoed across attendee reactions on social media following the event.
The stakes are straightforward. A treatment that can cure disease but only reaches patients near a handful of academic hospitals isn’t fully doing its job. Panels like this one put a spotlight on the plumbing behind medical breakthroughs, the unglamorous work of insurance rules, hospital financing, and geography that determines whether a cure on paper becomes a cure in practice for the people who need it.
Sources:
time.com, bloodcancerunited.org, ca.news.yahoo.com
